Mizuho reissued their buy rating on shares of Xeris Pharmaceuticals (NASDAQ:XERS) in a report issued on Tuesday, TipRanks reports. The brokerage currently has a $14.00 price objective on the stock.
XERS has been the topic of several other research reports. Piper Sandler initiated coverage on Xeris Pharmaceuticals in a research note on Tuesday, February 18th. They issued an overweight rating and a $12.00 target price on the stock. Zacks Investment Research lowered Xeris Pharmaceuticals from a buy rating to a hold rating and set a $4.50 target price on the stock. in a research note on Saturday, May 16th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $12.13.
NASDAQ:XERS opened at $5.35 on Tuesday. Xeris Pharmaceuticals has a 1-year low of $1.42 and a 1-year high of $12.94. The business’s 50-day moving average price is $2.94 and its two-hundred day moving average price is $4.99. The company has a current ratio of 4.82, a quick ratio of 4.72 and a debt-to-equity ratio of 2.16. The firm has a market capitalization of $202.99 million, a price-to-earnings ratio of -1.16 and a beta of 1.66.
In other Xeris Pharmaceuticals news, insider Paul R. Edick purchased 33,000 shares of the stock in a transaction on Friday, May 8th. The stock was bought at an average cost of $3.54 per share, for a total transaction of $116,820.00. Following the completion of the acquisition, the insider now directly owns 95,493 shares of the company’s stock, valued at $338,045.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John Patrick Shannon, Jr. purchased 22,000 shares of the stock in a transaction on Wednesday, May 13th. The stock was acquired at an average price of $3.55 per share, with a total value of $78,100.00. Following the completion of the acquisition, the insider now directly owns 117,493 shares of the company’s stock, valued at $417,100.15. The disclosure for this purchase can be found here. 7.43% of the stock is owned by corporate insiders.
Several large investors have recently bought and sold shares of the stock. FMR LLC grew its holdings in shares of Xeris Pharmaceuticals by 29.9% during the first quarter. FMR LLC now owns 2,963,018 shares of the company’s stock worth $29,749,000 after buying an additional 682,050 shares in the last quarter. ArrowMark Colorado Holdings LLC grew its holdings in shares of Xeris Pharmaceuticals by 21.4% during the first quarter. ArrowMark Colorado Holdings LLC now owns 2,341,902 shares of the company’s stock worth $4,567,000 after buying an additional 413,594 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Xeris Pharmaceuticals by 6.4% during the first quarter. BlackRock Inc. now owns 2,336,418 shares of the company’s stock worth $4,555,000 after buying an additional 139,671 shares in the last quarter. Citigroup Inc. grew its holdings in shares of Xeris Pharmaceuticals by 66,662.9% during the fourth quarter. Citigroup Inc. now owns 2,201,839 shares of the company’s stock worth $15,523,000 after buying an additional 2,198,541 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of Xeris Pharmaceuticals by 8.3% during the first quarter. State Street Corp now owns 542,031 shares of the company’s stock worth $1,057,000 after buying an additional 41,630 shares in the last quarter. Institutional investors and hedge funds own 62.48% of the company’s stock.
About Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Further Reading: Technical Analysis
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.